XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail) - AstraZeneca Agreements [Member] | 3 Months Ended
--- | ---
Mar. 31, 2018 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Right-of-return provisions for delivered items | $ 0
Royalty rate against projected net revenues | 40.00%
Discount rate applied | 17.50%
Co-development services, currently estimated continuation year | 2020
Manufacturing Commercial Supplies of Products [Member] |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Manufacturing commercial supplies of products, revenue recognized | $ 0
U.S./RoW and China [Member] |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Non-contingent upfront payments received | 402,200,000
Variable consideration related to payments for milestones considered probable of being achieved | 30,000,000
Variable consideration related to co-development billings | $ 682,200,000

X
- Definition Co-development services, estimated continuation year. + References No definition available. + Details
Name: | fgen_CoDevelopmentServicesEstimatedContinuationYear
Namespace Prefix: | fgen_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromNonContingentUpfrontPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Implied royalty rate used to find the net present value of future cash flows. + References No definition available. + Details
Name: | fgen_RoyaltyRateOnNetRevenue
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Variable consideration payment received related to co-development billings. + References No definition available. + Details
Name: | fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Variable consideration payment received upon achievement of milestone. + References No definition available. + Details
Name: | fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsDiscountRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from the sale of manufactured products, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_RevenueOtherManufacturedProducts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of estimated sales returns. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 15 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68051624&loc=d3e47468-111626 + Details
Name: | us-gaap_RevenueRecognitionSalesReturnsReserveForSalesReturns
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_ManufacturingCommercialSuppliesOfProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldAndChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |